Research programme: anti-angiogenesis antibodies - Bionomics/Genmab
Latest Information Update: 04 Nov 2017
At a glance
- Originator Bionomics; Genmab
- Class Antibodies
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Australia (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Denmark (Parenteral)
- 22 Feb 2008 This programme is still in active development